SNDX on Nasdaq

Syndax Pharmaceuticals Inc

American pharmaceutical preparations company based in Waltham.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Phathom Pharmaceuticals, Inc., Avadel Pharmaceuticals or Cryoport, Inc., or pick any stock.

  • TickerSNDX on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersWaltham, United States
  • Incorporated inDE2
  • Business address730 Third Avenue, 9Th Floor, New York, Ny 100172
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-158.4%Operating margin3
-165.6%Net margin3
627.8%Revenue growth, 20253
-441.6%Return on equity3
-$323.2MFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Net Product Revenues brought in 72% of the revenue Syndax Pharmaceuticals Inc broke down this way in fiscal 2025.

  1. Net Product Revenues$124.8M372%up 1526% from 2024
  2. Collaboration Revenue$42.4M325%
  3. Milestone Revenue$5.1M33%down 68% from 2024
Products and services by year
Products and services202320242025
Net Product Revenues$0$7.7M$124.8M
Collaboration Revenue$0$0$42.4M
Milestone Revenue$0$16.0M$5.1M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development59¢$258.8M
  • Selling, general and admin41¢$179.7M
  • Income tax0¢$433.0K

Out of $172.4M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$172.4M in 2025+11261% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $1.5M$1.5M20192020: $1.5M$1.5M2020+0%2021: $139.7M$139.7M2021+9110%2022: $0$020222023: $0$020232024: $23.7M$23.7M20242025: $172.4M$172.4M2025+628%
Operating income45673-$273.1M in 2025+375% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M0$100.0M2019: -$57.5M-$57.5M20192020: -$71.4M-$71.4M2020+24%2021: $26.2M$26.2M20212022: -$151.8M-$151.8M20222023: -$230.0M-$230.0M2023+52%2024: -$339.7M-$339.7M2024+48%2025: -$273.1M-$273.1M2025−20%
Net income45673-$285.4M in 2025+409% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M0$100.0M2019: -$56.0M-$56.0M20192020: -$73.2M-$73.2M2020+31%2021: $24.9M$24.9M20212022: -$149.3M-$149.3M20222023: -$209.4M-$209.4M2023+40%2024: -$318.8M-$318.8M2024+52%2025: -$285.4M-$285.4M2025−10%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Total Revenue$172.4M$23.7M$0
Cost of product sales$7.0M$826.0K$0
Research and development expenses$258.8M$241.6M$163.0M
Selling, general and administrative$179.7M$120.9M$66.9M
Total operating expenses$445.4M$363.4M$230.0M
Loss from operations-$273.1M-$339.7M-$230.0M
Royalty interest expense-$33.8M-$4.9M$0
Other interest (expense) income-$6.0K$1.0K-$208.0K
Interest income$22.7M$26.1M$21.2M
Other expense, net-$1.3M-$247.0K-$361.0K
Total other income-$12.3M$20.9M$20.6M
Net income-$285.4M-$318.8M-$209.4M
Net loss attributable to common stockholders-$285.4M-$318.8M-$209.4M
Basic loss per share attributable to common stockholders-$3.29-$3.72-$2.98
Diluted loss per share attributable to common stockholders-$3.29-$3.72-$2.98
Basic loss per share attributable to common stockholders86.6M shares85.6M shares70.4M shares
Diluted loss per share attributable to common stockholders86.6M shares85.6M shares70.4M shares

Compare Syndax Pharmaceuticals Inc with another company

Leadership

Who has led Syndax Pharmaceuticals Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Briggs Morrison2016–2021
  2. Michael A. Metzger2022–now

President

  1. Michael A. Metzger2016–2021
  2. Briggs Morrison2022–2023
  3. Neil Gallagher2023–now

Chief financial officer

  1. Allan Shaw2016
  2. Richard P. Shea2017–2020
  3. Daphne Karydas2020–2021
  4. Keith A. Goldan2022–now

Chief operating officer

  1. Michael A. Metzger2016–2021
20202025
Board members and other officers (22)

Timeline

  1. Feb 3, 2022New chief executive Michael A. Metzger becomes CEO11
  2. Mar 2, 2016New chief executive Briggs Morrison becomes CEO12

Filings

299 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 122 insider forms, 42 large holders, 58 other. The latest 20:

  1. Aug 7, 2026SCHEDULE 13G EDGAR
  2. Aug 4, 202610-Q EDGAR
  3. Aug 4, 20268-K EDGAR
  4. Jul 14, 20268-K EDGAR
  5. Jul 9, 20264 EDGAR
  6. Jul 8, 2026144 EDGAR
  7. Jun 12, 2026144 EDGAR
  8. Jun 12, 20264 EDGAR
  9. Jun 11, 2026144 EDGAR
  10. Jun 10, 20268-K EDGAR
  11. Jun 10, 20268-K EDGAR
  12. Jun 4, 2026DEFA14A EDGAR
  13. Jun 4, 20268-K EDGAR
  14. Jun 2, 20264 EDGAR
  15. Jun 2, 20264 EDGAR
  16. Jun 1, 2026144 EDGAR
  17. Jun 1, 2026144 EDGAR
  18. May 15, 2026SCHEDULE 13G/A EDGAR
  19. Apr 30, 2026SCHEDULE 13G EDGAR
  20. Apr 30, 2026ARS EDGAR

The 299 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 42 such filings since October 2021, the latest 10:

  1. Aug 7, 2026SCHEDULE 13G
  2. May 15, 2026SCHEDULE 13G/A
  3. Apr 30, 2026SCHEDULE 13G
  4. Mar 27, 2026SCHEDULE 13G/A
  5. Feb 9, 2026SCHEDULE 13G
  6. Jan 30, 2026SCHEDULE 13G/A
  7. Aug 18, 2025SCHEDULE 13G
  8. Aug 14, 2025SCHEDULE 13G/A
  9. May 7, 2025SCHEDULE 13G/A
  10. Mar 7, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.9,020,006$197.2M0.0%+765,580
Kynam Capital Management, LP8,050,959$176.0M9.7%No change
Goldman Sachs Group Inc5,861,265$128.1M0.0%+864,478
State Street Corp5,658,424$123.7M0.0%+1,228,348
Bank Of America Corp /de/4,045,094$88.4M0.0%−204,742
Vanguard Capital Management LLC3,927,892$85.9M0.0%+105,313
Deerfield Management Company, L.P.3,779,900$82.6M1.0%No change
Eversept Partners, LP2,798,210$61.2M3.3%−87,412
Geode Capital Management, LLC2,584,136$56.5M0.0%+427,078
Hood River Capital Management LLC2,564,279$56.1M0.4%+209,994
Kingdon Capital Management, L.l.c.2,500,000$54.6M7.4%No change
Franklin Resources Inc2,286,499$50.0M0.0%+136,420
Millennium Management LLC2,053,960$44.9M0.0%+1,854,436
Vanguard Portfolio Management LLC1,921,796$42.0M0.0%+184,655
UBS Group AG1,893,750$41.4M0.0%+740,088
Elmind Capital, LP1,855,000$40.6M10.2%No change
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1,790,173$39.1M0.0%+57,632
Candriam S.C.A.1,696,040$37.0M0.2%+770,708
Soleus Capital Management, L.P.1,628,039$35.6M1.2%−98,869
Two Sigma Investments, LP1,578,125$34.5M0.0%−1,471
Orbimed Advisors LLC1,542,000$33.7M0.6%+579,700
Nuveen, LLC1,364,575$29.8M0.0%−130,070
Mpm Bioimpact LLC1,333,523$29.2M1.8%−7,210
Aisling Capital Management LP1,316,806$28.8M6.1%No change
Woodline Partners LP1,250,760$27.3M0.1%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40